JP2024542235A5 - - Google Patents
Info
- Publication number
- JP2024542235A5 JP2024542235A5 JP2024529873A JP2024529873A JP2024542235A5 JP 2024542235 A5 JP2024542235 A5 JP 2024542235A5 JP 2024529873 A JP2024529873 A JP 2024529873A JP 2024529873 A JP2024529873 A JP 2024529873A JP 2024542235 A5 JP2024542235 A5 JP 2024542235A5
- Authority
- JP
- Japan
- Prior art keywords
- cys
- seq
- amino acid
- scfv
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163281954P | 2021-11-22 | 2021-11-22 | |
| US63/281,954 | 2021-11-22 | ||
| US202263322158P | 2022-03-21 | 2022-03-21 | |
| US63/322,158 | 2022-03-21 | ||
| US202263393750P | 2022-07-29 | 2022-07-29 | |
| US63/393,750 | 2022-07-29 | ||
| PCT/IB2022/061241 WO2023089587A1 (en) | 2021-11-22 | 2022-11-21 | Compositions comprising enhanced multispecific binding agents for an immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542235A JP2024542235A (ja) | 2024-11-13 |
| JP2024542235A5 true JP2024542235A5 (https=) | 2025-12-01 |
Family
ID=84370675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529873A Pending JP2024542235A (ja) | 2021-11-22 | 2022-11-21 | 免疫応答のための増強された多重特異性結合剤を含む組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250320304A1 (https=) |
| EP (1) | EP4436669A1 (https=) |
| JP (1) | JP2024542235A (https=) |
| KR (1) | KR20240111783A (https=) |
| AU (1) | AU2022392829A1 (https=) |
| CA (1) | CA3239224A1 (https=) |
| IL (1) | IL312968A (https=) |
| MX (1) | MX2024006205A (https=) |
| WO (1) | WO2023089587A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260051064A (ko) * | 2023-08-07 | 2026-04-15 | 얀센 바이오테크 인코포레이티드 | Gucy2c 항체 및 이의 용도 |
| WO2025243243A1 (en) | 2024-05-24 | 2025-11-27 | Janssen Biotech, Inc. | Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| SG190572A1 (en) | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| MX366910B (es) | 2013-03-15 | 2019-07-30 | Janssen Biotech Inc | Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes. |
| PE20171324A1 (es) * | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| US10882918B2 (en) | 2016-09-30 | 2021-01-05 | Hoffmann-La Roche Inc. | Bispecific T cell activating antigen binding molecules |
| CN114258400A (zh) * | 2019-08-15 | 2022-03-29 | 詹森生物科技公司 | 用于改进的单链可变片段的材料和方法 |
-
2022
- 2022-11-21 WO PCT/IB2022/061241 patent/WO2023089587A1/en not_active Ceased
- 2022-11-21 IL IL312968A patent/IL312968A/en unknown
- 2022-11-21 AU AU2022392829A patent/AU2022392829A1/en active Pending
- 2022-11-21 EP EP22817370.4A patent/EP4436669A1/en active Pending
- 2022-11-21 CA CA3239224A patent/CA3239224A1/en active Pending
- 2022-11-21 US US18/711,312 patent/US20250320304A1/en active Pending
- 2022-11-21 JP JP2024529873A patent/JP2024542235A/ja active Pending
- 2022-11-21 KR KR1020247020460A patent/KR20240111783A/ko active Pending
- 2022-11-21 MX MX2024006205A patent/MX2024006205A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210189011A1 (en) | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation | |
| JP7600327B2 (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| HRP20241775T1 (hr) | Bispecifična protutijela koja se specifično vežu na pd1 i lag3 | |
| JP2019533441A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| FI3561057T3 (fi) | Anti-cd3-vasta-aine ja vasta-ainetta sisältäviä molekyylejä | |
| CN119032104A (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2023139025A (ja) | 二重特異性抗原結合コンストラクト | |
| JP2024542235A5 (https=) | ||
| JP7826320B2 (ja) | 二重または多重特異性抗体｛Ｂｉ ｏｒ Ｍｕｌｔｉ－Ｓｐｅｃｉｆｉｃ Ａｎｔｉｂｏｄｙ｝ | |
| RU2024116415A (ru) | Композиции, содержащие улучшенные мультиспецифические связывающие агенты для иммунного ответа | |
| JP2022545368A5 (https=) | ||
| HK40050601A (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| RU2022103028A (ru) | Антитела против рецептора программируемой смерти pd-1 человека | |
| RU2021118725A (ru) | Биспецифические антитела, связывающиеся с tfr | |
| HK1247929A1 (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| HK1247929B (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation | |
| RU2022133024A (ru) | Анти-cd3 антитело и молекула, содержащая это антитело | |
| HK1194744B (en) | Dual variable region antibody-like binding proteins having cross-over binding region orientation |